Murat Dizbay

Murat Dizbay

Auto-generated profile, based on publicly available information

Murat Dizbay

Gazi Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Ankara, Turkiye

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
HEHakan Erdem
Hakan Erdem
AUAyşegül Ulu-Kilic
Ayşegül Ulu-Kilic
SKSelim Kilic
Selim Kilic
MKMustafa Karahocagil
Mustafa Karahocagil
Ghaydaa ShehataGhaydaa Shehata
Ghaydaa Shehata
HLHakan Leblebicioglu
Hakan Leblebicioglu
No data on whether brucellar meningitis or meningoencephalitis can be treated with oral antibiotics or whether an intravenous extended-spectrum cephalosporin, namely, ceftriaxone, which does not accumulate in phagocytes, should be added to the regimen exist in the literature. The aim of a study conducted in Istanbul, Turkey, was to compare the efficacy and tolerability of ceftriaxone-based antibiotic treatment regimens with those of an oral treatment protocol in patients with these conditions. This retrospective study enrolled 215 adult patients in 28 health care institutions from four different countries. The first protocol (P1) comprised ceftriaxone, rifampin, and doxycycline. The second protocol (P2) consisted of trimethoprim-sulfamethoxazole, rifampin, and doxycycline. In the third protocol (P3), the patients started with P1 and transferred to P2 when ceftriaxone was stopped. The treatment period was shorter with the regimens which included ceftriaxone (4.40 ± 2.47 months in P1, 6.52 ± 4.15 months in P2, and 5.18 ± 2.27 months in P3) ( P = 0.002). In seven patients, therapy was modified due to antibiotic side effects. When these cases were excluded, therapeutic failure did not differ significantly between ceftriaxone-based regimens ( n = 5/166, 3.0%) and the oral therapy ( n = 4/42, 9.5%) ( P = 0.084). The efficacy of the ceftriaxone-based regimens was found to be better ( n = 6/166 [3.6%] versus n = 6/42 [14.3%]; P = 0.017) when a composite negative outcome (CNO; relapse plus therapeutic failure) was considered. Accordingly, CNO was greatest in P2 (14.3%, n = 6/42) compared to P1 (2.6%, n = 3/117) and P3 (6.1%, n = 3/49) ( P = 0.020). Seemingly, ceftriaxone-based regimens are more successful and require shorter therapy than the oral treatment protocol.

26 May 2010 in Scandinavian Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MDMurat Dizbay
Murat Dizbay
OTOzlem Guzel Tunccan
Ozlem Guzel Tunccan
BSBusra Ergut Sezer
Busra Ergut Sezer
KHKenan Hizel
Kenan Hizel
The incidence, clinical characteristics, risk factors, antimicrobial susceptibility, and outcomes of nosocomial imipenem-resistant A. baumannii (IRAB) infections during a 5-y period (2003–2007) were retrospectively analyzed. A total of 720 patients with 925 episodes of A. baumannii infection were included in the study. A. baumannii infections were seen mostly in intensive care units. The incidence was 6.2 per 1000 admissions. The most common infections were pneumonias and bloodstream infections. Imipenem resistance among Acinetobacter strains increased significantly each y of the study (from 43.3% to 72.9%). Mortality was related to the presence of imipenem resistance, stay in intensive care unit, female gender, old age, and pneumonia. Haemodialysis, malignancy, and mechanical ventilation were significant risk factors for IRAB infections. Imipenem resistance was higher in strains isolated from patients with pneumonia. IRAB strains showed higher resistance rates to other antibiotics than imipenem-susceptible strains. The most active antimicrobial agents against A. baumannii were cefoperazone–sulbactam and netilmicin. The incidence of A. baumannii infections and imipenem resistance increased during the study period. IRAB infections should be considered in patients on mechanical ventilation and haemodialysis and in patients with malignancies.

31 July 2008 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MDM. Dizbay
M. Dizbay
AAA. Altuncekic
A. Altuncekic
BSB. Ergut Sezer
B. Ergut Sezer
KOK. Ozdemir
K. Ozdemir
DAD. Arman
D. Arman

1 October 2011 in Journal of Critical Care
Verified
Journal Article
Closed access
MTMelda Turkoglu
Melda Turkoglu
EMEmel Mirza
Emel Mirza
ÖTÖzlem Güzel Tunçcan
Özlem Güzel Tunçcan
GEGökmen Umut Erdem
Gökmen Umut Erdem
MDMurat Dizbay
Murat Dizbay
GSGülsan Türköz Sucak
Gülsan Türköz Sucak

27 November 2009 in The Journal of Antibiotics
Verified
Journal Article
Closed access
MDMurat Dizbay
Murat Dizbay
DTDerya Keten Tozlu
Derya Keten Tozlu
MCMeltem Yalinay Cirak
Meltem Yalinay Cirak
YIYasemin Isik
Yasemin Isik
KOKevser Ozdemir
Kevser Ozdemir
DADilek Arman
Dilek Arman

1 May 2009 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
OTOzlem Guzel Tunccan
Ozlem Guzel Tunccan
MDMurat Dizbay
Murat Dizbay
BSBusra Ergut Sezer
Busra Ergut Sezer
FAFirdevs Aktas
Firdevs Aktas
DADilek Arman
Dilek Arman
Background: Burkholderia cepacia has the potential to cause fatal infections in ICUs, and multidrug resistance makes them a serious threat in hospital settings. The aim of this study was to evaluate the epidemiology of B. cepacia infections in our hospital. Methodology: The incidence, clinical characteristics, antimicrobial susceptibility, and outcomes of nosocomial B. cepacia infections during a five-year period were retrospectively analysed according to the infection control committee records. Results: A total of 39 cases with nosocomial B. cepacia infection were included in the study. B. cepacia was identified from 0.7% of the nosocomial isolates. Its incidence was 0.26 per 1,000 admissions with 53.8% crude mortality rate. The most frequent nosocomial B. cepacia infection was pneumonia (58.9%), followed by bloodstream infections (25.6%), surgical site infections (7.6%), urinary tract infections, (5.1%), and skin-soft tissue infections (2.5%). Nosocomial B. cepacia infections were most commonly observed in intensive care units (61.5%). The most active antimicrobial agents were piperacillin-tazobactam, cefoperazone-sulbactam, and carbapenems. Conclusions: The incidence of nosocomial B. cepacia infections was rare in our hospital, and no outbreak was detected during the study period. However, infections caused by B. cepacia should be taken into consideration because of their high mortality due to multidrug resistance in ICU settings.